Neumora Therapeutics(US:NMRA) Prnewswire·2025-02-27 10:45Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [2][3]. Group 1: Allegations - The lawsuit claims that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [2]. - It is alleged that the company added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The complaint also states that the Phase Two Trials lacked adequate data, particularly concerning the patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 2: Class Action Details - The class period for the lawsuit commenced on or about September 15, 2023, and shareholders who purchased shares during this time are encouraged to register [1][3]. - The deadline for shareholders to seek lead plaintiff status is April 7, 2025, and there is no cost or obligation to participate in the case [3]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].